PD-1-M1-NK cells for advanced stomach or colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new type of immune cell therapy (PD-1-M1-NK cells) for people with advanced stomach or colorectal cancer that hasn't responded to at least two prior treatments. The goal is to see if these special cells can attack the cancer more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have advanced stomach or colorectal cancer that has gotten worse after at least two standard treatments (like chemo or immunotherapy).
- You must have a tumor sample that tests positive for PD-L1 (a protein on some cancer cells).
- You must have at least one tumor that can be measured on scans.
- You must not have had cell therapy (like CAR-T) before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new therapy where immune cells (TILs) from your tumor are modified to fight cancer more effectively. It's for people with advanced colorectal cancer who can't get standard treatments.
This trial tests a new type of immune cell therapy (gamma-delta T cells that have been modified to target PD-1) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if these cells can help your immune system fight the cancer.
This trial tests specially engineered immune cells (CAR-NK cells) designed to find and attack pancreatic cancer cells. The cells target specific proteins on cancer cells and may help people whose cancer has progressed despite prior treatment.
This trial tests a new type of immune cell therapy called CAR-NK cells that target two proteins (MSLN and MUC1) often found on pancreatic cancer cells. It is for people whose cancer has spread or cannot be removed, and who have already tried at least one standard treatment.
This trial tests a new natural killer (NK) cell therapy called NK510 for people with advanced gastric or colorectal cancer that has not responded to at least two prior treatments. The study aims to see if NK510 can help shrink tumors or slow the disease.
This trial tests a medicine called PD-1 (a type of immunotherapy that helps your immune system fight cancer), sometimes with chemotherapy, before surgery for a certain type of colorectal cancer. It is for people whose tumors have a specific DNA repair problem (dMMR or MSI-H) and whose cancer has not spread to distant organs.
Hear when a new Advanced Gastric or Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.